vs

Side-by-side financial comparison of Avidity Biosciences, Inc. (RNA) and WESTPORT FUEL SYSTEMS INC. (WPRT). Click either name above to swap in a different company.

WESTPORT FUEL SYSTEMS INC. is the larger business by last-quarter revenue ($12.5M vs $12.5M, roughly 1.0× Avidity Biosciences, Inc.). WESTPORT FUEL SYSTEMS INC. runs the higher net margin — -274.8% vs -1398.3%, a 1123.5% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -11.4%). WESTPORT FUEL SYSTEMS INC. produced more free cash flow last quarter ($-6.4M vs $-156.9M).

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

Westport Innovations is a company that develops alternative fuel, low-emissions technologies to allow engines to operate on clean-burning fuels such as compressed natural gas (CNG), liquefied natural gas (LNG), hydrogen and biofuels such as landfill gas. Headquartered in Vancouver, British Columbia, Canada, where the company was founded, Westport also has facilities in France, Sweden, Italy, China, Australia and the United States.

RNA vs WPRT — Head-to-Head

Bigger by revenue
WPRT
WPRT
1.0× larger
WPRT
$12.5M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+445.5% gap
RNA
434.0%
-11.4%
WPRT
Higher net margin
WPRT
WPRT
1123.5% more per $
WPRT
-274.8%
-1398.3%
RNA
More free cash flow
WPRT
WPRT
$150.4M more FCF
WPRT
$-6.4M
$-156.9M
RNA

Income Statement — Q3 FY2025 vs Q2 FY2025

Metric
RNA
RNA
WPRT
WPRT
Revenue
$12.5M
$12.5M
Net Profit
$-174.4M
$-34.3M
Gross Margin
6.7%
Operating Margin
-1513.5%
-8.1%
Net Margin
-1398.3%
-274.8%
Revenue YoY
434.0%
-11.4%
Net Profit YoY
-117.0%
-690.4%
EPS (diluted)
$-1.27
$-1.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RNA
RNA
WPRT
WPRT
Q3 25
$12.5M
Q2 25
$3.8M
$12.5M
Q1 25
$1.6M
Q4 24
$3.0M
Q3 24
$2.3M
$4.9M
Q2 24
$2.0M
$14.1M
Q1 24
$3.5M
Q4 23
$2.2M
Net Profit
RNA
RNA
WPRT
WPRT
Q3 25
$-174.4M
Q2 25
$-157.3M
$-34.3M
Q1 25
$-115.8M
Q4 24
$-102.3M
Q3 24
$-80.4M
$-3.9M
Q2 24
$-70.8M
$5.8M
Q1 24
$-68.9M
Q4 23
$-60.4M
Gross Margin
RNA
RNA
WPRT
WPRT
Q3 25
Q2 25
6.7%
Q1 25
Q4 24
Q3 24
13.6%
Q2 24
16.7%
Q1 24
Q4 23
Operating Margin
RNA
RNA
WPRT
WPRT
Q3 25
-1513.5%
Q2 25
-4448.7%
-8.1%
Q1 25
-8360.9%
Q4 24
-4069.6%
Q3 24
-4200.9%
-43.9%
Q2 24
-4040.4%
-54.9%
Q1 24
-2178.6%
Q4 23
-3043.5%
Net Margin
RNA
RNA
WPRT
WPRT
Q3 25
-1398.3%
Q2 25
-4089.3%
-274.8%
Q1 25
-7360.0%
Q4 24
-3439.5%
Q3 24
-3441.7%
-79.3%
Q2 24
-3461.8%
41.2%
Q1 24
-1943.4%
Q4 23
-2756.2%
EPS (diluted)
RNA
RNA
WPRT
WPRT
Q3 25
$-1.27
Q2 25
$-1.21
$-1.98
Q1 25
$-0.90
Q4 24
$-0.80
Q3 24
$-0.65
$-0.22
Q2 24
$-0.65
$0.34
Q1 24
$-0.79
Q4 23
$-0.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RNA
RNA
WPRT
WPRT
Cash + ST InvestmentsLiquidity on hand
$350.2M
$6.1M
Total DebtLower is stronger
$977.0K
Stockholders' EquityBook value
$1.9B
$108.9M
Total Assets
$2.1B
$272.1M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RNA
RNA
WPRT
WPRT
Q3 25
$350.2M
Q2 25
$243.9M
$6.1M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$575.8M
Q1 24
$471.4M
Q4 23
$185.1M
Total Debt
RNA
RNA
WPRT
WPRT
Q3 25
Q2 25
$977.0K
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23
Stockholders' Equity
RNA
RNA
WPRT
WPRT
Q3 25
$1.9B
Q2 25
$1.2B
$108.9M
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$1.5B
$149.3M
Q2 24
$1.2B
$151.5M
Q1 24
$830.9M
Q4 23
$500.8M
Total Assets
RNA
RNA
WPRT
WPRT
Q3 25
$2.1B
Q2 25
$1.4B
$272.1M
Q1 25
$1.5B
Q4 24
$1.6B
Q3 24
$1.6B
Q2 24
$1.3B
Q1 24
$951.5M
Q4 23
$628.6M
Debt / Equity
RNA
RNA
WPRT
WPRT
Q3 25
Q2 25
0.01×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RNA
RNA
WPRT
WPRT
Operating Cash FlowLast quarter
$-156.2M
$-5.6M
Free Cash FlowOCF − Capex
$-156.9M
$-6.4M
FCF MarginFCF / Revenue
-1257.6%
-51.6%
Capex IntensityCapex / Revenue
5.7%
6.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RNA
RNA
WPRT
WPRT
Q3 25
$-156.2M
Q2 25
$-199.7M
$-5.6M
Q1 25
$-124.8M
Q4 24
$-99.9M
Q3 24
$-65.6M
$-11.7M
Q2 24
$-65.0M
$1.5M
Q1 24
$-70.4M
Q4 23
$16.5M
Free Cash Flow
RNA
RNA
WPRT
WPRT
Q3 25
$-156.9M
Q2 25
$-203.0M
$-6.4M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
$-11.9M
Q2 24
$-65.5M
$262.0K
Q1 24
$-71.3M
Q4 23
$15.6M
FCF Margin
RNA
RNA
WPRT
WPRT
Q3 25
-1257.6%
Q2 25
-5277.1%
-51.6%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
-243.4%
Q2 24
-3204.6%
1.9%
Q1 24
-2012.3%
Q4 23
713.1%
Capex Intensity
RNA
RNA
WPRT
WPRT
Q3 25
5.7%
Q2 25
86.9%
6.6%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
3.8%
Q2 24
26.0%
8.9%
Q1 24
25.8%
Q4 23
39.4%
Cash Conversion
RNA
RNA
WPRT
WPRT
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.26×
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons